DarioHealth Corp.

Good morning, ladies and gentlemen, and welcome to the Dario Health First Quarter 2026 Results Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Wednesday, May 13, 2026. I would now like to turn the conference over to Zoe Harrison, VP Accounting and Corporate Development at Dario Health. Zoe, please go ahead.

Thank you, Operator, and good morning, everyone. Thank you for joining us today for a discussion of Dario Health's first quarter 2026 financial results. Leading the call today will be Erez Rafael, Chief Executive Officer of Dario Health. He'll be joined by our President and Chief Commercial Officer, Steven Nelson, and Hen Franco, our Chief Financial Officer. An audio recording and webcast replay for today's call will also be available online as detailed in the press release invite for this call. For the benefit of those who may be listening to the replay or archived webcast, this call is being held on Wednesday, May 13th, 2026. This morning, we issued a press release announcing our financial results for the first quarter of 2026. The copy of the release can be found on the investor relations page of Dario Health website. I'd like to remind you that on this call, management will make forward-looking statements within the meaning of the federal securities laws. For example, the company is using forward-looking statements when it discusses expected revenue growth and contribution from 2025 signed accounts, its path to profitability and cash flow breakeven, the continued reduction in operating expenses and losses, its expansion of channel partnerships and covered lives reach, its expected revenue and scaling from partner-led and off-cycle opportunities, expected onboarding and implementation of large enterprise accounts, expected growth and conversion of commercial pipeline opportunities, expected expansion into care delivery, claims-based and outcomes-based models, expected benefits from care delivery and green key health partnerships, expected growth in recurring revenue and operating leverage, expected advantages and future impact of DarioIQ and proprietary data assets, expected improvements in member engagement, retention and outcomes beliefs regarding competitive positioning and market opportunity, and the expected outcomes of the company's strategic review process, including potential strategic transactions. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the company's control, including the risks described from time to time in its SEC filing. The company's results may differ materially from those projections. These statements involve material risks and uncertainties that could cause actual results or events to materially differ. Accordingly, you should not place undue reliance on these statements. I encourage you to review the company's filings with the SEC, including without limitation the company's annual report on Form 10-K, which identifies specific factors that may cause actual results or events that differ materially from those described in the forward-looking statement. With that, I'll hand it over to Erez Rafael, Chief Executive Officer of Dario Health.

Good morning, everyone, and thank you for joining us. We started 2026 with continued momentum. Q1 marked our second consecutive quarter of sequential revenue growth while we continue to reduce our operating expenses. The financial trajectory is on track, and Hen will walk you through the details shortly. I want to focus my comment today on three things. The continued expansion of our channel ecosystem, the scale we are now operationalizing from the account signed in 2025, And the next strategic step in our platform, Moving Closer to Care, which opens new revenue streams for us. I'll also share some strong numbers on how our value IQ AI engine is further boosting member engagement. Last quarter, we described two compounding layers in the core of our growth strategy. Layer one, channel partnership that gives access to millions of covered lives through a single commercial relationship. There are two multi-condition platform that captures a far greater share of each account's population. That figure is now playing out and is being accelerated. Our channel partnerships continues to grow and entered the contracting stage with a new channel partner. The largest in Dario's history, the relationship comes from a major day one anchor account, one of the largest hospital network in Northeastern United States. With this partnership, we expect to access approximately 65 million additional covered lives and roughly 3,500 employer relationships. Combined with our existing relationships with Solera, and other blue-chip channel partners, this will bring our distribution reach to over 175 million covered lives. We had a strong sales cycle at the end of 2025 and closed out the year with nearly $13 million in contracted and next-stage business, which remains on track to contribute to revenue later this year and in 2027. In parallel, our challenge model is producing contract flow outside of the traditional benefit cycle calendar, even when we share the commercial details. The third area I want to spend time on is an important strategic step we are taking. How we are evolving the platform itself to move closer to care. We have built a strong digital health foundation, a scalable, recurring, per-engaged member per month revenue model with measurable outcomes. That call continues. What is changing is what we are extending beyond engagement and support into actual delivery of care. We believe Dario is uniquely positioned to lead this shift, and the reason is straightforward. We have built one of the deepest bodies of clinical evidence in digital health. More than 100 peer-reviewed clinical studies, more than any other company in our category, demonstrating real measurable outcomes. This level of validation is what the credential and providers require. It is also what makes outcomes-based and claims-based revenue models possible for us. We are building beyond our core ability to engage members and support improved outcomes to be able to change. We are building to directly impact clinical outcomes, close care gaps, and participate in the medical spend associated with those outcomes. To accelerate this strategy, we are working with a care delivery partner Stephen will share more on this work shortly. The foundation underneath everything I've just described is what we have always said. It's data. Dario is a data company that leverages generative and agentic AI on top of one of the most valuable proprietary clinical data sets in digital health. The reason we are confident is that the position is structured. We are fully vertically integrated. We design and manufacture our FDA-cleared connected devices. Those devices generate continuous biochemical and other clinical data directly from the members in real time. The data flows into our platform. Our analytics and AI run on top of it. From hardware to AI, the stack is ours. We don't license it, rent it, or depend on third-party input. Today, we have more than 13 billion proprietary real world data points to show clinical outcomes across multiple conditions at the individual level. That is the kind of data set that takes a decade to build and cannot be replicated quickly. ValueIQ, our proprietary AI engine, Framed on that dataset is the product expression of that advantage. It delivers personalized, real-time clinical recommendation that the general purpose model cannot match because no general purpose model has access to longitudinal data of this depth tied to a real outcome. DarioIQ is now in active deployment, and the early results are meaningful. Our behavioral triggered engagement program where the DarioCure identifies the right intervention at the right moment for each member based on the personal data signature are delivering up to 40% improvement in member retention and up to 55% lift in active session versus control group. These are early data points, but they are directional. They tell us AI-led is producing measurable behavioral change today, and that the same data fly away The mode is what compounded. The implication is direct. As AI capabilities advance, our positions . Every advance in AI raises the value of the underlying data. We own this data. To put this together, our channel ecosystem continues to scale. The accounts beside in 2025 are converting into revenues. and we are evolving the platform from digital engagement into care delivery, backed by clinical evidence and proprietary data and a foundation that compounds with every member we add. We are building a business that is more deeply integrated into how healthcare is delivered, paid for, and measured. This is exactly where the market is going, and that is where Dario is positioned to lead. With that, I will turn the call over to Stephen.